Learn about Avation plc's financial performance, industry outlook, and investment potential in this discussion with Canaccord Genuity's Damian Brewer...
Travis Perkins plc announced unaudited full year results for 2023, facing challenges in the construction industry. CEO Nick Roberts discusses strategic actions taken...
Darktrace plc (LON:DARK) has appointed David Smith as Chief People Officer. With over 15 years' experience in HR, he will lead the global people strategy to drive future growth...
Intertek Group plc (LON:ITRK) announces impressive full year results, with revenue growth, margin progression, and strong cash flow. CEO André Lacroix highlights key achievements and outlines positive outlook for 2024...
Ashtead Group plc (LON:AHT) delivers strong performance with revenue up 14% and rental revenue up 11% in nine months ending 31 January 2024. CEO Brendan Horgan comments on strategic growth plans and market conditions...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
Learn about Avation plc's financial performance, industry outlook, and investment potential in this discussion with Canaccord Genuity's Damian Brewer...
Travis Perkins plc announced unaudited full year results for 2023, facing challenges in the construction industry. CEO Nick Roberts discusses strategic actions taken...
Darktrace plc (LON:DARK) has appointed David Smith as Chief People Officer. With over 15 years' experience in HR, he will lead the global people strategy to drive future growth...
Intertek Group plc (LON:ITRK) announces impressive full year results, with revenue growth, margin progression, and strong cash flow. CEO André Lacroix highlights key achievements and outlines positive outlook for 2024...
Ashtead Group plc (LON:AHT) delivers strong performance with revenue up 14% and rental revenue up 11% in nine months ending 31 January 2024. CEO Brendan Horgan comments on strategic growth plans and market conditions...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
